PM 012Alternative Names: PM012 tablet - PuriMED
Latest Information Update: 25 Apr 2016
At a glance
- Originator PuriMED
- Class Antidementias; Herbal medicines
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase II Alzheimer's disease
Most Recent Events
- 31 May 2012 Phase-II clinical trials in Alzheimer's disease in South Korea (PO)
- 31 Dec 2008 Preclinical trials in Dementia in South Korea (unspecified route)